MARKET

KTTAW

KTTAW

Pasithea Therapeutics Corp
NASDAQ
0.0066
+0.0010
+17.86%
Closed 15:39 06/09 EDT
OPEN
0.0057
PREV CLOSE
0.0056
HIGH
0.0067
LOW
0.0049
VOLUME
400
TURNOVER
--
52 WEEK HIGH
0.1198
52 WEEK LOW
0.0034
MARKET CAP
--
P/E (TTM)
-0.0033
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at KTTA last week (0601-0605)?
Weekly Report · 1d ago
Pasithea Therapeutics granted Orphan Drug Designation for PAS-004 by FDA
TipRanks · 06/02 11:30
Pasithea Therapeutics' PAS-004 Receives FDA Orphan Drug Designation For ALS
NASDAQ · 06/02 11:21
Pasithea Therapeutics Says FDA Grants Orphan Drug Designation To PAS-004 For Treatment Of Amyotrophic Lateral Sclerosis
Benzinga · 06/02 11:08
Pasithea says FDA grants orphan drug designation for PAS-004 in ALS
PUBT · 06/02 11:05
PASITHEA THERAPEUTICS ANNOUNCES ORPHAN DRUG DESIGNATION BY FDA OF PAS-004 FOR TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
Reuters · 06/02 11:02
Pasithea Therapeutics Announces Orphan Drug Designation by FDA of PAS-004 for Treatment of Amyotrophic Lateral Sclerosis (ALS)
Barchart · 06/02 06:02
Weekly Report: what happened at KTTA last week (0525-0529)?
Weekly Report · 06/01 09:25
More
About KTTAW
Pasithea Therapeutics Corp. is a biotechnology company focused on the discovery, research and development of treatments for central nervous system (CNS) disorders and other diseases. The Company is advancing a pipeline of three therapeutic product candidates, with a focus on its lead product candidate, PAS-004, a macrocyclic mitogen-activated protein kinase, or MEK inhibitor. PAS-004 is a small molecule allosteric inhibitor of MEK 1 and 2 (MEK 1/2) for potential use in the treatment of a range of RASopathies, including neurofibromatosis type 1 (NF1) and a number of oncology indications, among others. Its remaining two programs, PAS-001 and PAS-003, are in the earlier stages of development and are based on novel targets for the treatment of CNS disorders that it believes address limitations in the treatment paradigm of the indications it plans to address, which are amyotrophic lateral sclerosis (ALS) for its PAS-003 program, and schizophrenia for its PAS-001 program.

Webull offers Pasithea Therapeutics Corp stock information, including NASDAQ: KTTAW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KTTAW stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KTTAW stock methods without spending real money on the virtual paper trading platform.